Appili Therapeutics Inc Class A (APLIF) Stock Statistics & Valuation Metrics
Total Valuation
Appili Therapeutics Inc Class A has a market cap or net worth of $473.59K. The enterprise value is $15.17M.
- Market Cap
- $473.59K
- Enterprise Value
- $15.17M
Share Statistics
Appili Therapeutics Inc Class A has 132,366,120 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 132,366,120
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
Appili Therapeutics Inc Class A’s return on equity (ROE) is 0.24 and return on invested capital (ROIC) is 148.65%.
- Return on Equity (ROE)
- 0.24
- Return on Assets (ROA)
- -2.15
- Return on Invested Capital (ROIC)
- 148.65%
- Return on Capital Employed (ROCE)
- 0.39
- Revenue Per Employee
- 34.88K
- Profits Per Employee
- -605.82K
- Employee Count
- 7
- Asset Turnover
- 0.12
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Appili Therapeutics Inc Class A is -0.14. Appili Therapeutics Inc Class A’s PEG ratio is 0.00.
- PE Ratio
- -0.14
- PS Ratio
- 1.75
- PB Ratio
- -0.03
- Price to FCF
- -0.50
- Price to Operating Cash Flow
- -0.49
- PEG Ratio
- 0.00
Income Statement
In the last 12 months, Appili Therapeutics Inc Class A had revenue of 244.18K and earned -4.24M in profits. Earnings per share was -0.03.
- Revenue
- 244.18K
- Gross Profit
- 236.09K
- Operating Income
- -6.53M
- Pretax Income
- -4.14M
- Net Income
- -4.24M
- EBITDA
- -6.53M
- Earnings Per Share (EPS)
- -0.03
Cash Flow
In the last 12 months, operating cash flow was -1.35M and capital expenditures 36,976, giving a free cash flow of -1.32M billion.
- Operating Cash Flow
- -1.35M
- Free Cash Flow
- -1.32M
- Free Cash Flow per Share
- -0.01
Dividends & Yields
Appili Therapeutics Inc Class A pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -199.06%
- Earnings Yield
- -707.48%
Stock Price Statistics
- Beta
- 0.75
- 52-Week Price Change
- -45.00%
- 50-Day Moving Average
- 0.01
- 200-Day Moving Average
- 0.01
- Relative Strength Index (RSI)
- ―
- Average Volume (3m)
- ―
Important Dates
Appili Therapeutics Inc Class A upcoming earnings date is Nov 12, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 14, 2026
- Next Earnings Date
- Nov 12, 2026
- Ex-Dividend Date
- ―
Financial Position
Appili Therapeutics Inc Class A as a current ratio of 0.11, with Debt / Equity ratio of -74.64%
- Current Ratio
- 0.11
- Quick Ratio
- 0.11
- Debt to Market Cap
- 6.97
- Net Debt to EBITDA
- -1.98
- Interest Coverage Ratio
- -6.45
Taxes
In the past 12 months, Appili Therapeutics Inc Class A has paid 96.85K in taxes.
- Income Tax
- 96.85K
- Effective Tax Rate
- -0.02
Enterprise Valuation
Appili Therapeutics Inc Class A EV to EBITDA ratio is -2.37, with an EV/FCF ratio of -10.51.
- EV to Sales
- 36.56
- EV to EBITDA
- -2.37
- EV to Free Cash Flow
- -10.51
- EV to Operating Cash Flow
- -10.23
Balance Sheet
Appili Therapeutics Inc Class A has $138.68K in cash and marketable securities with $13.33M in debt, giving a net cash position of -$13.19M billion.
- Cash & Marketable Securities
- $138.68K
- Total Debt
- $13.33M
- Net Cash
- -$13.19M
- Net Cash Per Share
- -$0.10
- Tangible Book Value Per Share
- -$0.14
Margins
Gross margin is 98.46%, with operating margin of -1606.24%, and net profit margin of -1236.07%.
- Gross Margin
- 98.46%
- Operating Margin
- -1606.24%
- Pretax Margin
- -1211.54%
- Net Profit Margin
- -1236.07%
- EBITDA Margin
- -1545.81%
- EBIT Margin
- -1547.35%
Analyst Forecast
The average price target for Appili Therapeutics Inc Class A is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- 252.01%
- EPS Growth Forecast
- -91.97%
